Drug Profile
Research programme: nanoparticle therapeutics - Tharimmune
Alternative Names: Nanoxane™; NPG-114; NPG-215; NPG-384Latest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator Hillstream BioPharma; NanoProteagen
- Developer NanoProteagen
- Class Cytokine genes; Diterpenes; Paclitaxels; Small molecules; Taxanes
- Mechanism of Action Cytokine stimulants; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Cancer
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Breast-cancer(Metastatic disease, Second-line therapy or greater) in USA
- 28 Oct 2020 No recent reports of development identified for preclinical development in Cancer in USA
- 09 Sep 2016 Preclinical trials in Breast cancer (Metastatic disease, Second-line therapy or greater) in USA (unspecified route) before September 2016